Corporate News & Publications

CLINUVEL's company releases, including archives.

Monday, 27 April 2015 15:59

Appendix 4C - Q3 FY15

Tuesday, 31 March 2015 16:59

Clinuvel relocates Melbourne office

Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that its head office in Melbourne has relocated. The new address, which will also be the Company’s Registered Address, is: Level 5160 Queen StMelbourneVictoria, Australia 3000 All telephone and fax numbers remain the same. - End - About Clinuvel Pharmaceuticals Limited Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) is a global biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders. With its unique expertise in understanding the interaction of light and human skin, the company has identified patient populations with…
Friday, 20 March 2015 17:16

Appendix 3B - March 20

Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA: UR9; ADR: CLVLY) today announced that its drug SCENESSE® (afamelanotide 16mg) has featured in an editorial in the peer-reviewed Journal of Investigative Dermatology. The editorial – “An α-MSH analogue in erythropoietic protoporphyria” – reviews both Clinuvel’s program and the broader history of the bench to bedside development of α-MSH as a therapeutic drug. In their concluding remarks, the authors note that “[t]he approval of afamelanotide by the European Medicines Agency in late 2014 can be regarded as a breakthrough for α-MSH in clinical medicine.” SCENESSE® was approved under exceptional circumstances by the European Medicines…
Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that its vitiligo program will feature in presentations to be given at this week’s American Academy of Dermatology (AAD) 73rd Annual Meeting in San Francisco. Data from Clinuvel’s vitiligo program will be reviewed and discussed by experts involved in the CUV102 and CUV103 clinical trials, where SCENESSE® has been used as a combination repigmentation treatment for darker skinned vitiligo patients. “We are seeing an increasing recognition of the need to treat vitiligo in practical dermatology, which is reflected in the number of presentations featuring Clinuvel’s program,” Clinuvel’s Director, Clinical…
Thursday, 12 March 2015 07:03

Clinuvel Newsletter - March 2015

Friday, 06 March 2015 18:37

S&P Dow Jones Indices Announces March 2015 Quarterly Rebalance of the S&P/ASX Indices

Monday, 02 March 2015 19:30

Appendix 3B - March 2

Wednesday, 25 February 2015 18:18

Appendix 4D - Half Yearly Report to Dec 31 2014

Friday, 30 January 2015 19:27

Appendix 4C - Q2 FY15

Quick Links